Latest research report on “RNAi for Therapeutic Market” now available at high quality database of ReportsnReports.com with market size, share, trends, competitive and statistical analysis. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample Research Copy @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5553704
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
This report contains market size and forecasts of RNAi for Therapeutic in Global, including the following market information:
Global RNAi for Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global RNAi for Therapeutic market was valued at 181.1 million in 2021 and is projected to reach US$ 2031.2 million by 2028, at a CAGR of 41.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
siRNA Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics and Benitec Biopharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the RNAi for Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global RNAi for Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global RNAi for Therapeutic Market Segment Percentages, by Type, 2021 (%)
Global RNAi for Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global RNAi for Therapeutic Market Segment Percentages, by Application, 2021 (%)
Global RNAi for Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global RNAi for Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
– North America
– – US
– – Canada
– – Mexico
– – Germany
– – France
– – U.K.
– – Italy
– – Russia
– – Nordic Countries
– – Benelux
– – Rest of Europe
– – China
– – Japan
– – South Korea
– – Southeast Asia
– – India
– – Rest of Asia
– South America
– – Brazil
– – Argentina
– – Rest of South America
– Middle East & Africa
– – Turkey
– – Israel
– – Saudi Arabia
– – UAE
– – Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies RNAi for Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies RNAi for Therapeutic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
– Alnylam Pharmaceuticals
– Arbutus Biopharma (Tekmira)
– Dicerna Pharmaceuticals
– Mirna Therapeutics
– Quark Pharmaceuticals
– RXi Pharmaceuticals
– Silence Therapeutics
– Benitec Biopharma
– miRagen Therapeutics
More information about Discount offers (25% or More) @ https://www.reportsnreports.com/contacts/discount.aspx?name=5553704
About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
We provide 24/7 online and offline support to our customers.
E-mail: [email protected]
Phone: +1 888 391 5441